Colinearity of reverse transcriptase inhibitor resistance mutations detected by population-based sequencing

被引:12
作者
Gonzales, MJ
Johnson, E
Dupnik, KM
Imamichi, T
Shafer, RW
机构
[1] Stanford Univ, Div Infect Dis, Stanford, CA 94305 USA
[2] NCI, Sci Applicat Int Corp, Frederick, MD 21701 USA
关键词
HIV-1; reverse transcriptase; drug resistance; clone; genome;
D O I
10.1097/00126334-200312010-00006
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
High-level resistance to multiple drugs is often detected by directly sequencing uncloned polymerase chain reaction products (population-based sequencing). It is not known, however, if this method of identifying mutations gives an accurate picture of individual viral genomes. To determine how often multidrug-resistant isolates consist of clones containing every mutation present in the population-based sequence, a mean of 2.8 molecular clones was sequenced from the plasma of 25 heavily treated persons whose population-based sequence contained multiple reverse transcriptase (RT) inhibitor resistance mutations (71 clones). The 25 population-based sequences contained a mean of 5.7 nucleoside reverse transcriptase inhibitor (NRTI) resistance mutations and 1.2 nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance mutations. The 71 clones contained a mean of 5.3 NRTI resistance mutations and 1.0 NNRTI resistance mutations. Sequences of clones closely resembled the population-based sequence: 3 6 (51%) clones had each of the RT inhibitor mutations present in the population-based sequence, 25 (35%) had all but 1 RT inhibitor mutation, 4 (6%) had all but 2 RT inhibitor mutations, 3 (4%) bad all but 3 RT inhibitor mutations, and 3 (4%) had all but 4 RT inhibitor mutations. Phenotypic testing of 29 clones showed that most clones were resistant to nearly all NRTIs and that those with NNRTI resistance mutations were also resistant to multiple NNRTIs. These data show that in heavily treated persons, most RT inhibitor resistance mutations are present in the same viral genomes (colinear) and that multidrug resistance often occurs within individual clones as well as within virus populations.
引用
收藏
页码:398 / 402
页数:5
相关论文
共 23 条
[1]   Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy [J].
Bacheler, LT ;
Anton, ED ;
Kudish, P ;
Baker, D ;
Bunville, J ;
Krakowski, K ;
Bolling, L ;
Aujay, M ;
Wang, XV ;
Ellis, D ;
Becker, MF ;
Lasut, AL ;
George, HJ ;
Spalding, DR ;
Hollis, G ;
Abremski, K .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (09) :2475-2484
[2]   Individual contributions of mutant protease and reverse transcriptase to viral infectivity, replication, and protein maturation of antiretroviral drug-resistant human immunodeficiency virus type 1 [J].
Bleiber, G ;
Munoz, M ;
Ciuffi, A ;
Meylan, P ;
Telenti, A .
JOURNAL OF VIROLOGY, 2001, 75 (07) :3291-3300
[3]  
Calvez V, 2002, ANTIVIR THER, V7, P211
[4]  
Clavel F, 2000, Adv Pharmacol, V49, P41
[5]   HIV POPULATION-DYNAMICS IN-VIVO - IMPLICATIONS FOR GENETIC-VARIATION, PATHOGENESIS, AND THERAPY [J].
COFFIN, JM .
SCIENCE, 1995, 267 (5197) :483-489
[6]   Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor [J].
Condra, JH ;
Holder, DJ ;
Schleif, WA ;
Blahy, OM ;
Danovich, RM ;
Gabryelski, LJ ;
Graham, DJ ;
Laird, D ;
Quintero, JC ;
Rhodes, A ;
Robbins, HL ;
Roth, E ;
Shivaprakash, M ;
Yang, T ;
Chodakewitz, JA ;
Deutsch, PJ ;
Leavitt, RY ;
Massari, FE ;
Mellors, JW ;
Squires, KE ;
Steigbigel, RT ;
Teppler, H ;
Emini, EA .
JOURNAL OF VIROLOGY, 1996, 70 (12) :8270-8276
[7]   Reduction in human immunodeficiency virus type 1 mutations associated with drug resistance after initiating new therapeutic regimens in pretreated patients [J].
Devereux, HL ;
Loveday, C ;
Youle, M ;
Sabin, CA ;
Burke, A ;
Johnson, MA .
JOURNAL OF INFECTIOUS DISEASES, 2000, 181 (05) :1804-1807
[8]   Extended spectrum of HIV-1 reverse transcriptase mutations in patients receiving multiple nucleoside analog inhibitors [J].
Gonzales, MJ ;
Wu, TD ;
Taylor, J ;
Belitskaya, F ;
Kantor, R ;
Israelski, D ;
Chou, S ;
Zolopa, AR ;
Fessel, WJ ;
Shafer, RW .
AIDS, 2003, 17 (06) :791-799
[9]   Changes in human immunodeficiency virus type 1 populations after treatment interruption in patients failing antiretroviral therapy [J].
Hance, AJ ;
Lemiale, V ;
Izopet, J ;
Lecossier, D ;
Joly, V ;
Massip, P ;
Mammano, F ;
Descamps, D ;
Brun-Vézinet, F ;
Clavel, F .
JOURNAL OF VIROLOGY, 2001, 75 (14) :6410-6417
[10]   A novel human immunodeficiency virus type 1 reverse transcriptase mutational pattern confers phenotypic lamivudine resistance in the absence of mutation 184V [J].
Hertogs, K ;
Bloor, S ;
De Vroey, V ;
Van den Eynde, C ;
Dehertogh, P ;
Van Cauwenberge, A ;
Stürmer, M ;
Alcorn, T ;
Wegner, S ;
Van Houtte, M ;
Miller, V ;
Larder, BA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (03) :568-573